Browse articles from EyeWorld.org related to myopia. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA accepts new drug application for pharmaceutical aiming to treat pediatric myopia
➤ FDA approves treatment for macular telangiectasia type 2
➤ Survey reveals perspectives of patients with glaucoma
➤ New wearable vision testing platform
➤ Seeking Fast Track Designation for investigational treatment of neuropathic corneal pain
➤ Fast Track Designation granted to gene therapy targeting X-linked retinoschisis
➤ ASCRS news and events
➤ Fast Track Designation granted for investigational retinitis pigmentosa therapy
➤ Three-month data for first-in-class dual inflammasome inhibitor for geographic atrophy
➤ Clinical updates for sustained-release drug implant treating glaucoma
➤ Gene therapy program receives Rare Pediatric Disease Designation
➤ Study: lasting effect of multifocal contact lenses for myopia progression
➤ ASCRS news and events
➤ FDA grants De Novo classification to ocular pressure adjusting pump
➤ Inaugural ‘State of Dry Eye’ survey
➤ Study: potentially higher risk for blinding ocular condition with semaglutide use
➤ Wet AMD treatment implant reintroduced
➤ Acquisition news
➤ ASCRS news and events
➤ Allogenic cell therapy receives FDA designations
➤ Robot delivers new treatment for wet AMD
➤ Health-related quality of life measure proposed for MIGS
➤ Company meets with FDA for pediatric myopia drug candidate
➤ ASCRS news and events
➤ Twelve-month results for Phase 2 trial evaluating heat-therapy system for MGD
➤ Topline results from targeted photobiomodulation for treatment of progressive myopia
➤ Enrollment complete in Phase 3 trials to evaluate new wet AMD therapy
➤ ‘Low tech’ way to prioritize cataract surgery
➤ ASCRS news and events
➤ Study: artificial intelligence matches/outperforms ophthalmologists
➤ Primary endpoint met in Phase 3 trial using an antibody to treat thyroid eye disease
➤ FDA grants Breakthrough Device Designation to novel spectacle design
➤ ASCRS news and events
➤ Primary, secondary endpoints met in Phase 2 wet AMD trial
➤ Modifications made to investigational glaucoma treatment device
➤ Positive Phase 1/2 data from clinical trial for treatment of Leber congenital amaurosis
➤ Results from first-in-human study of siRNA treatment for AMD
➤ Possibility of a minimally invasive approach for treating AMD
➤ ASCRS news and events
➤ FDA approves drop for mydriasis reversal
➤ Inventors of OCT honored with ‘American Nobel Prize’
➤ Preservative-free latanoprost begins U.S. launch
➤ Enrollment complete in myopia treatment trial
➤ ASCRS news and events
An NIH-funded trial in the U.S. sought to evaluate the effect of low-dose atropine drops on slowing myopia in a pediatric population and found an “absence of treatment benefit.” This is unlike other studies, such as that involving children in East Asia, that did show a positive effect of low-dose atropine.
➤ Study: low-dose atropine doesn’t slow myopia progression
➤ Adverse events reported after use of FDA-approved geographic atrophy drug
➤ Phase 1 data for synthetic cannabinoid being investigated for glaucoma
➤ Enrollment complete in study evaluating topical diabetic retinopathy therapy
➤ Enrollment update for Phase 2b trial that could reduce AMD treatment burden
➤ ASCRS news and events
